

## Sanofi | Aubagio

### Aubagio (DHODH inhibitor): Publication: Switching to Teriflunomide reduced relapse frequency, stabilized MRI lesions, & increased mean EDSS vs. prior use of DMTs in pwRMS (Oct 17, 2025)

sanofi

Once-daily  
AUBAGIO®


- Data from Sanofi sponsored study to examine the effectiveness of Aubagio (Teriflunomide) in patients with MS who switched to Teriflunomide from other DMTs published in the [Medicine](#) journal
- **RMS analysis**
  - Mean ARR decreased by 80.8% following switching to Teriflunomide, from 0.26 relapses at 1 year pre-index to 0.05 relapses at 2 years post-index (change: -0.21 [0.47]; P < .001)
  - Stable or improved MRI lesions in most patients following switching to Teriflunomide (1 year post-index: 95.1%; 2 years post-index: 97.6%) vs. prior switching to Teriflunomide therapy (1 year pre-index, 80.1%)
- **aSPMS subgroup analysis**
  - In the subset of patients with aSPMS (n = 32), mean ARR reduced from 1-year pre-index to 2-years post-index (0.4 vs 0.03; change: -0.38 [P < .001]). EDSS, Montreal Cognitive Assessment, & timed 25-foot walk test scores remained stable in patients with aSPMS
- Switching to Teriflunomide was associated with a **reduced frequency of relapses, in addition to stabilised or improved MRI lesion status, and an increased mean EDSS score, vs. prior treatment with other DMTs** (i.e., before switching)
  - These real-world data suggest that Teriflunomide may be an **appropriate treatment option for patients with RMS who have experienced unsuccessful therapy with previous DMT**

Source: [Medicine](#)

#### Commentary/Background

- Findings from this study indicate that **pwRMS (RMS or aSPMS) experienced a reduction in relapses & evidence for recovery from lymphopenia**. Other markers of disability worsening, including EDSS, remained stable after switching to Teriflunomide highlighting the consistent efficacy profile of Teriflunomide
  - These observations compare favour-

ably with other real-world analyses of pwRMS on Teriflunomide, including the larger observational [TAURUS-MS](#) study (N = 1,128), which reported a significant reduction in ARR from 0.87 (in the 2 yrs prior study entry) to 0.35 during 2 years of Teriflunomide treatment & the smaller [TACO](#) study (N = 47), which reported an ARR of 0.14 during 2 years of Teriflunomide treatment



## Sanofi | Aubagio

### Aubagio (DHODH inhibitor): EMA label updated to include potential skin ulcer risk post treatment with Aubagio along with guidance for therapy administratio (Dec 09, 2025)

sanofi

Once-daily  
AUBAGIO®

#### LIGHT NEWS

- Sanofi's Aubagio [EMA](#) label has been updated to include statements on skin ulcers under section of **special warnings & precautions for use**
  - **In ANNEX I – CLINICAL PARTICULARS (4):** In the Special warnings & precautions for use section (4.4), the subsection of **Skin reactions** has been updated, as follows:
    - Skin ulcers & impaired wound healing may potentially occur in patients during therapy with Aubagio
    - If an Aubagio-associated skin ulcer is suspected, if skin ulcers persist despite appropriate therapy, or if there is a high risk for impaired wound healing after surgery, **consider Aubagio discontinuation** & an accelerated drug elimination procedure
    - The decision to resume Aubagio should be based on clinical judgment of adequate wound healing
- Additionally, **ANNEX III – under Labelling and Package Leaflet** section, **Warnings & Precautions** subsection is updated with precautionary instructions for patients on development of skin reactions post intake of Aubagio have been added

Source: [EMA label](#)

### Sanofi launched new corporate campaign called "chase the miracles of science" inclusive of SPMS patient story (Nov 12, 2025)

- Sanofi launched a new corporate campaign, "[chase the miracles of science](#)" inclusive of patient's stories from the US, France, China, and Germany living with disease conditions targeted by Sanofi (including MS) & several employee stories
- **Key Highlights:**
  - **Patient story in MS**
  - [Céline](#), a two-time French para-surfing champion with **secondary progressive multiple sclerosis (SPMS)** is highlighted in campaign with messaging "**Find the biggest wave and conquer it not once but twice**"
    - Sanofi highlighted its therapeutic expertise: respiratory, neurology, dermatology, oncology, autoimmune diseases, & rare diseases
    - The campaign was launched at the end of October & globally promotions started last week

**Sanofi intends to roll out more patient, advocates and scientists' stories as film** throughout this year and next

Sources: [Fierce Pharma](#), [Sanofi patient stories](#), [Céline's Story](#), [Chasing the miracles campaign](#)